Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
NVCT
Stock Latest News
Ratings
Nuvectis Pharma: Buy Rating Backed by NXP900’s Potential to Overcome EGFR/ALK Inhibitor Resistance in NSCLC
29d ago
NVCT
Premium
Ratings
Positive Recommendation on Nuvectis Pharma Driven by Promising Lead Candidate and Milestone Clinical Studies
30d ago
NVCT
Premium
The Fly
Nuvectis Pharma announces initiation of Phase 1b study of NXP900
30d ago
NVCT
Premium
Ratings
NXP900: A Promising New Standard in Post-TKI NSCLC Treatment
1M ago
NVCT
Premium
Ratings
Buy Rating for Nuvectis Pharma’s NXP900 Driven by Promising Efficacy and Development Progress
2M ago
NVCT
Premium
Company Announcements
Nuvectis Pharma Reports Progress in Oncology Drug Development
2M ago
NVCT
Premium
The Fly
Nuvectis Pharma reports Q3 EPS (44c), consensus (25c)
2M ago
NVCT
Premium
The Fly
Nuvectis Pharma reports Q3 net loss $7.5M vs $4.2M last year
2M ago
NVCT
Premium
Company Announcements
Nuvectis Pharma’s Phase 1 Study of NXP900: A Potential Game-Changer in Cancer Treatment
3M ago
NVCT
Premium
Ratings
Promising Safety and Efficacy of Nuvectis Pharma’s NXP900 Drives Buy Recommendation
3M ago
NVCT
Premium
The Fly
Nuvectis Pharma provides highlights from NXP900 poster presentations
3M ago
NVCT
Premium
Company Announcements
Nuvectis Pharma Appoints Juan Sanchez to Board
4M ago
8K
NVCT
Premium
The Fly
Nuvectis Pharma appoints Juan Sanchez to board of directors
4M ago
NVCT
Premium
The Fly
Nuvectis Pharma initiates NXP900 program
5M ago
NVCT
Premium
Ratings
Nuvectis Pharma’s Strategic Focus on NXP900 and Positive Outlook Amidst Promising Developments
5M ago
NVCT
Premium
Company Announcements
Nuvectis Pharma Reports Q2 2025 Financial Results and Progress
5M ago
NVCT
Premium
The Fly
Nuvectis Pharma reports Q2 EPS (30c) vs. (26c) last year
5M ago
NVCT
Premium
Ratings
Strategic Pipeline Reprioritization and Promising Clinical Progress Drive Buy Rating for Nuvectis Pharma
5M ago
NVCT
Premium
The Fly
Nuvectis Pharma price target lowered to $10 from $15 at H.C. Wainwright
5M ago
NVCT
Premium
Ratings
Strategic Focus on NXP900 Drives Buy Rating for Nuvectis Pharma
6M ago
NVCT
Premium
The Fly
Nuvectis Pharma provides final clinical data update from NXP800 Phase 1b study
6M ago
NVCT
Premium
Ratings
Promising Potential of NXP900 in Combination Therapy for Resistant Lung Cancer Justifies Buy Rating
6M ago
NVCT
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
